Rocket Pharma Scores Fast-Track Voucher for Kids' Rare Disease Drug

2026-06316 — Issuance of Priority Review Voucher; Rare Pediatric Disease Product; YUVIWEL (navepegritide)

The FDA just gave Ascendis Pharma a special priority review voucher for their rare pediatric disease drug, YUVIWEL, which helps kids with achondroplasia grow taller. This voucher speeds up future drug reviews and can be a valuable asset, saving time and potentially money. Approved on February 27, 2026, this move highlights the FDA’s commitment to fast-tracking treatments for rare childhood conditions.

2026-06314 — Determination That INAPSINE (Droperidol) Injection, 2.5 Milligrams/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

The FDA has decided that INAPSINE (droperidol) injection wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can keep being approved and sold as long as they follow the rules. Patients and healthcare providers can keep trusting this medicine without worry, and drug makers can continue their work without delays or extra costs.

2026-06294 — Consideration of Acceptable Market Name Change for Certain Rockfish (Sebastes spp.); Request for Information

The FDA wants to hear from fishermen, seafood sellers, and fish lovers about possibly changing the official market names for certain rockfish species. This update aims to make fish labels clearer and safer for everyone, with comments open until May 1, 2026. If the name changes happen, it could affect how these fish are sold and marketed, so your input matters!

2026-06187 — Notice of Decision on a Hearing Request Regarding a Proposal To Refuse To Approve a New Drug Application for TRADIPITANT Capsules

The FDA has decided not to approve Vanda Pharmaceuticals’ new drug, TRADIPITANT capsules, meant to treat symptoms of gastroparesis. Vanda asked for a hearing to challenge this, but the FDA denied it. This means patients and doctors will have to wait longer for this treatment, and Vanda faces delays and extra costs as they figure out their next move.

2026-05913 — Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications; Correction

The FDA fixed a mistake about pulling approvals for 72 generic drug applications. One drug, a valproic acid capsule from Upsher-Smith Laboratories, won’t lose its approval because the company asked to keep it. This means the drug stays available, and the change took effect before October 23, 2025.

2026-05772 — General and Plastic Surgery Devices; Reclassification of Optical Diagnostic Devices for Melanoma Detection and Electrical Impedance Spectrometers, To Be Renamed Software-Aided Adjunctive Diagnostic Devices for Use on Skin Lesions by Physicians Trained in the Diagnosis and Management of Skin Cancer

The FDA is changing the rules for certain skin cancer detection devices, moving them from a strict category (Class III) to a less strict one (Class II) with special safety checks. These devices, now called software-aided tools for skin lesion diagnosis, must be used by doctors trained in skin cancer. The new rules start April 24, 2026, making it easier and safer for doctors to use these helpful tools without extra costly hurdles.

Previous: 2026-06378 — Parts and Accessories Necessary for Safe Operation; Application for Exemption Renewal From Loomis Armored US, LLC

Loomis Armored US, LLC wants to renew a 5-year exemption to keep using armored trucks with welded-shut cab doors and add two extra doors behind the cab. This affects Loomis’s armored vehicle operations and could impact safety rules for these trucks. The public can comment on this request until May 4, 2026, before the government decides whether to approve it.

Next: 2026-06380 — Combined Notice of Filings #1

The Federal Energy Regulatory Commission got a bunch of filings from power companies about ownership changes and a new solar project claiming special status. These updates mostly affect energy companies and could impact how they operate or report their business. If you want to comment, you’ve got until mid to late April 2026 to speak up!